{"id":57151,"date":"2026-02-14T11:20:12","date_gmt":"2026-02-14T03:20:12","guid":{"rendered":"https:\/\/flcube.com\/?p=57151"},"modified":"2026-02-14T11:20:13","modified_gmt":"2026-02-14T03:20:13","slug":"astellas-ventana-cldn18-assay-wins-nmpa-approval-as-first-companion-diagnostic-for-vyloy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57151","title":{"rendered":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY"},"content":{"rendered":"\n

Astellas Pharma Inc.<\/strong> (TYO: 4503<\/a>) announced that its VENTANA CLDN18 (43-14A) Assay<\/strong> has received approval from China’s National Medical Products Administration (NMPA)<\/strong>, becoming the first and currently only companion diagnostic (CDx) reagent<\/strong> in China to identify patients eligible for VYLOY (zolbetuximab)<\/strong> treatment. The immunohistochemistry (IHC) assay<\/strong>, approved alongside VYLOY’s December\u202f2024 NMPA authorization<\/strong>, enables precision patient selection<\/strong> for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong>\u2014a biomarker-defined population<\/strong> representing ~30-40% of advanced gastric cancer patients<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Astellas Pharma Inc.<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Device<\/strong><\/td>VENTANA CLDN18 (43-14A) Assay \u2013 Immunohistochemistry (IHC) companion diagnostic<\/td><\/tr>
Indication<\/strong><\/td>Gastric or GEJ adenocarcinoma<\/td><\/tr>
Target Biomarker<\/strong><\/td>CLDN18.2 expression<\/td><\/tr>
Associated Therapy<\/strong><\/td>VYLOY (zolbetuximab) \u2013 CLDN18.2-targeted monoclonal antibody<\/td><\/tr>
VYLOY Approval<\/strong><\/td>December\u202f25,\u202f2024<\/strong> \u2013 First-line CLDN18.2+, HER2- gastric\/GEJ cancer + chemotherapy<\/td><\/tr>
Strategic Significance<\/strong><\/td>First and only approved CDx for VYLOY in China<\/strong>; precision medicine infrastructure<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Context & Biomarker Strategy<\/h2>\n\n\n\n
Parameter<\/th>CLDN18.2 Profile<\/th>VENTANA Assay Value<\/th><\/tr><\/thead>
Prevalence<\/strong><\/td>30-40% of gastric\/GEJ adenocarcinomas<\/strong> express CLDN18.2<\/td>Identifies treatable population<\/strong>; excludes HER2+ patients (contraindicated)<\/td><\/tr>
Expression Pattern<\/strong><\/td>Tight junction protein<\/strong> in gastric mucosa; upregulated in cancer<\/strong><\/td>IHC detection standardization<\/strong> for consistent scoring<\/strong><\/td><\/tr>
Treatment Eligibility<\/strong><\/td>CLDN18.2-positive, HER2-negative<\/strong><\/td>Companion diagnostic requirement<\/strong> for VYLOY reimbursement and prescribing<\/strong><\/td><\/tr>
Clinical Benefit<\/strong><\/td>SPOTLIGHT\/GLOW trials<\/strong>: VYLOY + chemo showed significant PFS\/OS improvement<\/strong> vs. chemo alone<\/td>Assay-validated efficacy<\/strong>; regulatory co-approval<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China Gastric Cancer Burden<\/strong><\/td>>400,000 new cases annually<\/strong>; world’s highest incidence<\/strong>; precision medicine adoption accelerating<\/strong><\/td><\/tr>
CLDN18.2 Competition<\/strong><\/td>VYLOY first-to-market<\/strong> in China (Dec\u202f2024); competing with CAR-T (IMC002, satricabtagene)<\/strong> and ADCs<\/strong> in development; VENTANA assay creates barrier to entry<\/strong><\/td><\/tr>
Companion Diagnostic Moat<\/strong><\/td>First and only approved CDx<\/strong> establishes testing infrastructure lock-in<\/strong>; hospital laboratory standardization<\/strong> favors VENTANA platform<\/td><\/tr>
Astellas Integrated Strategy<\/strong><\/td>Drug + diagnostic co-development<\/strong> ensures optimal patient identification<\/strong>; maximizes VYLOY commercial potential<\/strong>; regulatory efficiency<\/strong><\/td><\/tr>
Global Alignment<\/strong><\/td>VENTANA CLDN18 approved in US, EU, Japan<\/strong>; China approval completes major market coverage<\/strong>; harmonized testing standards<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial & Reimbursement Implications<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>NMPA approval; hospital laboratory onboarding<\/td>Q1\u202f2026<\/td><\/tr>
Testing Scale-Up<\/strong><\/td>Pathology laboratory IHC platform installation; technician training<\/td>2026<\/td><\/tr>
VYLOY Commercialization<\/strong><\/td>Biomarker-driven prescribing; NRDL negotiation for drug + test<\/td>2026-2027<\/td><\/tr>
Patient Access<\/strong><\/td>CLDN18.2 screening integration into gastric cancer workup<\/td>2026+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding VENTANA CLDN18 assay adoption in Chinese hospital laboratories, VYLOY commercial performance, and CLDN18.2 testing market expansion. Actual results may differ due to pathology infrastructure variability, competitive CDx development, and VYLOY pricing\/reimbursement negotiations.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Astellas Pharma Inc. (TYO: 4503) announced that its VENTANA CLDN18 (43-14A) Assay has received approval…<\/p>\n","protected":false},"author":1,"featured_media":57152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[22],"tags":[353,15,1177],"class_list":["post-57151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-device","tag-astellas-pharma","tag-product-approvals","tag-tyo-4503"],"yoast_head":"\nAstellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57151\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57151\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T03:20:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T03:20:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY\",\"datePublished\":\"2026-02-14T03:20:12+00:00\",\"dateModified\":\"2026-02-14T03:20:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1401.webp\",\"keywords\":[\"Astellas Pharma\",\"Product approvals\",\"TYO: 4503\"],\"articleSection\":[\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57151#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57151\",\"name\":\"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1401.webp\",\"datePublished\":\"2026-02-14T03:20:12+00:00\",\"dateModified\":\"2026-02-14T03:20:13+00:00\",\"description\":\"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57151\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57151#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY - Insight, China's Pharmaceutical Industry","description":"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57151","og_locale":"en_US","og_type":"article","og_title":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY","og_description":"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.","og_url":"https:\/\/flcube.com\/?p=57151","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T03:20:12+00:00","article_modified_time":"2026-02-14T03:20:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57151#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57151"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY","datePublished":"2026-02-14T03:20:12+00:00","dateModified":"2026-02-14T03:20:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57151"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57151#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","keywords":["Astellas Pharma","Product approvals","TYO: 4503"],"articleSection":["Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57151#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57151","url":"https:\/\/flcube.com\/?p=57151","name":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57151#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57151#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","datePublished":"2026-02-14T03:20:12+00:00","dateModified":"2026-02-14T03:20:13+00:00","description":"Astellas Pharma Inc. announced that its VENTANA CLDN18 (43-14A) Assay has received approval from China's National Medical Products Administration (NMPA), becoming the first and currently only companion diagnostic (CDx) reagent in China to identify patients eligible for VYLOY (zolbetuximab) treatment. The immunohistochemistry (IHC) assay, approved alongside VYLOY's December\u202f2024 NMPA authorization, enables precision patient selection for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma\u2014a biomarker-defined population representing ~30-40% of advanced gastric cancer patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57151#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57151"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57151#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","width":1080,"height":608,"caption":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57151#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas\u2019 VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57151"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57151\/revisions"}],"predecessor-version":[{"id":57153,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57151\/revisions\/57153"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57152"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}